JP2020522543A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522543A5 JP2020522543A5 JP2019567598A JP2019567598A JP2020522543A5 JP 2020522543 A5 JP2020522543 A5 JP 2020522543A5 JP 2019567598 A JP2019567598 A JP 2019567598A JP 2019567598 A JP2019567598 A JP 2019567598A JP 2020522543 A5 JP2020522543 A5 JP 2020522543A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- motomeko
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023127275A JP2023145720A (ja) | 2017-06-07 | 2023-08-03 | 変異ＩｇＧ六量体に基づく治療用抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762516489P | 2017-06-07 | 2017-06-07 | |
| US62/516,489 | 2017-06-07 | ||
| US201862614801P | 2018-01-08 | 2018-01-08 | |
| US62/614,801 | 2018-01-08 | ||
| PCT/EP2018/065071 WO2018224609A1 (en) | 2017-06-07 | 2018-06-07 | Therapeutic antibodies based on mutated igg hexamers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127275A Division JP2023145720A (ja) | 2017-06-07 | 2023-08-03 | 変異ＩｇＧ六量体に基づく治療用抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522543A JP2020522543A (ja) | 2020-07-30 |
| JP2020522543A5 true JP2020522543A5 (enExample) | 2021-07-26 |
Family
ID=62636167
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567598A Pending JP2020522543A (ja) | 2017-06-07 | 2018-06-07 | 変異ＩｇＧ六量体に基づく治療用抗体 |
| JP2023127275A Withdrawn JP2023145720A (ja) | 2017-06-07 | 2023-08-03 | 変異ＩｇＧ六量体に基づく治療用抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127275A Withdrawn JP2023145720A (ja) | 2017-06-07 | 2023-08-03 | 変異ＩｇＧ六量体に基づく治療用抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200247897A1 (enExample) |
| EP (1) | EP3635005A1 (enExample) |
| JP (2) | JP2020522543A (enExample) |
| KR (1) | KR20200027944A (enExample) |
| CN (1) | CN111328335A (enExample) |
| BR (1) | BR112019025328A2 (enExample) |
| MA (1) | MA49259A (enExample) |
| MX (1) | MX2019014407A (enExample) |
| TW (1) | TW201919692A (enExample) |
| WO (1) | WO2018224609A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190115057A (ko) | 2017-02-10 | 2019-10-10 | 젠맵 비. 브이 | 폴리펩티드 변이체 및 그의 용도 |
| EP3788074A1 (en) | 2018-05-03 | 2021-03-10 | Genmab B.V. | Antibody variant combinations and uses thereof |
| US20220315661A1 (en) * | 2019-05-09 | 2022-10-06 | Genmab B.V. | Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| WO2022018294A1 (en) * | 2020-07-23 | 2022-01-27 | Genmab B.V. | A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma |
| MX2023008302A (es) | 2021-01-13 | 2023-09-25 | Visterra Inc | Anticuerpos humanizados contra el receptor 1 del componente 5a del complemento y métodos de uso de estos. |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| DE60013773T2 (de) | 1999-02-03 | 2005-11-10 | Biosante Pharmaceuticals, Inc. | Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| KR20040081422A (ko) | 2001-11-01 | 2004-09-21 | 유에이비 리서치 파운데이션 | 종양 괴사 인자-관련 세포사멸-유도 리간드 수용체에선택적인 항체와 다른 치료제와의 복합물 |
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| GEP20135917B (en) | 2006-03-17 | 2013-09-10 | Biogen Idec Inc | Stabilized polypeptide compositions |
| ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| ES2702087T3 (es) | 2007-06-21 | 2019-02-27 | Macrogenics Inc | Diacuerpos covalentes y sus usos |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| ES2524553T3 (es) | 2008-06-17 | 2014-12-10 | Apogenix Gmbh | Receptores multiméricos de TNF |
| SG172254A1 (en) | 2008-12-19 | 2011-07-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| US20120070432A1 (en) | 2009-05-28 | 2012-03-22 | Amgen Inc. | Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine |
| KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| PL2560993T3 (pl) | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| RU2608640C2 (ru) | 2010-08-16 | 2017-01-23 | Новиммун С.А. | Способы получения мультиспецифичных и мультивалентных антител |
| RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
| RU2013110876A (ru) | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| CN102654260B (zh) | 2011-09-29 | 2014-09-03 | 北京京东方光电科技有限公司 | 一种背光源和液晶显示器 |
| HRP20201004T1 (hr) | 2011-12-20 | 2020-10-16 | Medimmune, Llc | Modificirani polipeptidi za skelete bispecifičnog protutijela |
| DK2838917T3 (da) | 2012-04-20 | 2019-08-26 | Merus Nv | Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler |
| AU2013285355A1 (en) * | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| EP2684896A1 (en) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| KR20240123420A (ko) | 2013-01-10 | 2024-08-13 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| WO2017093448A1 (en) * | 2015-12-01 | 2017-06-08 | Genmab B.V. | Anti-dr5 antibodies and methods of use thereof |
-
2018
- 2018-06-07 MX MX2019014407A patent/MX2019014407A/es unknown
- 2018-06-07 TW TW107119651A patent/TW201919692A/zh unknown
- 2018-06-07 MA MA049259A patent/MA49259A/fr unknown
- 2018-06-07 BR BR112019025328-9A patent/BR112019025328A2/pt not_active Application Discontinuation
- 2018-06-07 KR KR1020207000017A patent/KR20200027944A/ko not_active Ceased
- 2018-06-07 WO PCT/EP2018/065071 patent/WO2018224609A1/en not_active Ceased
- 2018-06-07 JP JP2019567598A patent/JP2020522543A/ja active Pending
- 2018-06-07 US US16/618,722 patent/US20200247897A1/en not_active Abandoned
- 2018-06-07 EP EP18731987.6A patent/EP3635005A1/en active Pending
- 2018-06-07 CN CN201880050867.4A patent/CN111328335A/zh active Pending
-
2023
- 2023-08-03 JP JP2023127275A patent/JP2023145720A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11103579B2 (en) | Combination of DR5 agonist and anti-PD-1 antagonist and methods of use | |
| JP2020522543A5 (enExample) | ||
| JP2019500869A5 (enExample) | ||
| JP7126941B2 (ja) | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ | |
| JP2019501151A5 (enExample) | ||
| CN108602889A (zh) | 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体 | |
| JP2020501531A5 (enExample) | ||
| CN113825527A (zh) | 用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合 | |
| JP7548924B2 (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| ES2951864T3 (es) | Combinación de un anticuerpo biespecífico ERBB-2/ERBB-3 con terapia endocrina para el cáncer de mama | |
| JPWO2020232019A5 (enExample) | ||
| RU2836467C2 (ru) | Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований | |
| CN121175334A (zh) | 在治疗癌症中的使用pd-l1抑制剂的新辅助免疫疗法 | |
| CA3009161C (en) | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer | |
| CN116615238A (zh) | 用于治疗癌症和减轻细胞因子释放综合征的抗体组合 | |
| CN120152716A (zh) | 包括抗cd19抗体和ezh2调节剂的治疗 | |
| EA049485B1 (ru) | Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака | |
| NZ743316A (en) | Anti-dr5 antibodies and methods of use thereof | |
| RU2019128199A (ru) | 1-(4-амино-5-бром-6-(1h-пиразол-1-ил)пиримидин-2-ил)-1h-пиразол-4-ол и его применение в лечении рака | |
| NZ743316B2 (en) | Anti-dr5 antibodies and methods of use thereof | |
| EA042623B1 (ru) | Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли |